The effect of prostaglandin analogs and prostamide on central corneal thickness.
OBJECTIVE
The aim of this study was to verify the influence of prostaglandin analogs and prostamide on central corneal thickness (CCT).


METHODS
A prospective analysis was done of CCT in glautomatous patients submitted to monotherapy with prostaglandin analogs (latanoprost 0.005% or travoprost 0.004%) or prostamide (bimatoprost 0.03%) during an 8-week period. A control group of patients without any ocular medication was also evaluated. CCT measurements were performed with a commercially available ultrasound pachymeter. A total of 73 patients were included in this study. Mean age was 68.5 +/- 9.2 (range, 48-85) years old.


RESULTS
A statistically significant reduction in CCT was observed in all groups, except the control group (n = 21): Bimatoprost 0.03% group (n = 21): 544.41 +/- 35.4 vs. 540.35 +/- 35.9 microm (P = 0.039); travoprost 0.004% group (n = 17): 538.47 +/- 32.0 vs. 532.25 +/- 30.4 microm (P = 0.009); latanoprost 0.005% group (n = 14): 548.57 +/- 32.4 vs. 543.88 +/- 35.6 microm (P = 0.036).


CONCLUSIONS
Topical therapy with prostaglandin analogs and bimatoprost is associated with CCT reduction over a period of at least 8 weeks.
Hatanaka
Marcelo
M
Department of Opthalmology, University of São Paulo School of Medicine, São Paulo, Brazil. info@centroavancado.net
Vessani
Roberto M
RM
Elias
Isalina R
IR
Morita
Celso
C
Susanna
Remo
R
D000287:Administration, Topical; D000368:Aged; D000369:Aged, 80 and over; D000577:Amides / Q000494:pharmacology / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000494:pharmacology* / Q000627:therapeutic use; D000069580:Bimatoprost; D003008:Cloprostenol / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D003315:Cornea / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000473:pathology; D003941:Diagnostic Techniques, Ophthalmological; D005260:Female; D005902:Glaucoma, Open-Angle / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D000077338:Latanoprost; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011461:Prostaglandins F, Synthetic / Q000494:pharmacology / Q000627:therapeutic use; D011465:Prostaglandins, Synthetic / Q000494:pharmacology* / Q000627:therapeutic use; D000069557:Travoprost; D014463:Ultrasonography
D000577:Amides; D000959:Antihypertensive Agents; D011461:Prostaglandins F, Synthetic; D011465:Prostaglandins, Synthetic; D003008:Cloprostenol; D000077338:Latanoprost; D000069580:Bimatoprost; D000069557:Travoprost